G-Omeprazole 40 mg/vial substantially reduces the antiplatelet activity of Clopidogrel through competitive inhibition of CYP2C19, potentially increasing the risk of cardiovascular events in patients who depend on Clopidogrel for cardiovascular protection (e.g., post-cardiac stenting)
Insufficient human clinical trials have led to a lack of data to determine a safe dose
This quickly boosts vitamin B12 levels in those who are low
(PubMed) Yuan S, Mason AM, Carter P, Burgess S, Larsson SC
The mechanism explaining this selectivity is straightforward
Keep perspective: the strongest evidence for AHK-Cu is a single dish-and-follicle study, its better-evidenced route is topical, and nothing here is a human-use recommendation weigh that before any self-experimentation